Thermo Fisher Scientific, a leading life sciences company, has reported strong quarterly profit and revenue, beating Wall Street estimates. The company’s quarterly revenue grew 10% to $11.99 billion, above analysts’ estimate of $11.70 billion.
Segment Performance
The company’s laboratory products and biopharma services segment posted a near 12% rise in revenue to $6.69 billion. The life-sciences solutions segment recorded an increase of about 13% in revenue to $2.82 billion.
CEO Marc Casper stated, ‘Our end markets continue to strengthen and we’re making great progress enhancing our capabilities.’ The company’s strong performance is attributed to improving customer demand, which has lifted sales across all its business segments.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.